Electroacupuncture for women with urgency-predominant mixed urinary incontinence: secondary analysis of a randomized noninferiority trial

World J Urol. 2020 Apr;38(4):1035-1042. doi: 10.1007/s00345-019-02828-1. Epub 2019 Jun 3.

Abstract

Objective: To compare the effects and safety of electroacupuncture (EA) and the integration of pelvic floor muscle training (PFMT) and solifenacin in women with urgency-predominant mixed urinary incontinence (MUI).

Methods: The study was a secondary analysis of a randomized noninferiority trial which recruited 500 women with MUI and randomized 178 with urgency-predominant MUI to either receive 12-week EA treatment and 24-week follow-up or 36-week PFMT-solifenacin treatment. Clinical response was defined as at least 50% reduction in average 24-h urgency incontinence episode frequency (IEF), measured by 72-h voiding diary through weeks 1-12.

Results: Of the patients randomized, 173 completed the study. The clinical response was 45.78% in EA group, similar with 50.0% in PFMT-solifenacin group, with a difference of - 3.54 (95% CI - 19.08 to 12.0; P = 0.66). In both groups, the proportion of patients with at least 50% reduction of IEF and stress IEF were improved, while the score of ICIQ-SF, episodes of urination, nocturia and urgency, 1-h amount of urinary leakage (AUL), proportion of patients using pads and the number consumed were all decreased after 12-week treatment. The effects could sustain till 36 weeks. Adverse events occurred less in EA group.

Conclusions: EA might reduce IEF, AUL and improve the life quality of female patients with urgency-predominant MUI. The effect may sustain till 36 weeks.

Keywords: Acupuncture; Non-inferior; Pelvic floor muscle training; Solifenacin; Stress; Urge.

Publication types

  • Comparative Study
  • Equivalence Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Combined Modality Therapy
  • Electroacupuncture*
  • Exercise Therapy*
  • Female
  • Humans
  • Middle Aged
  • Muscarinic Antagonists / therapeutic use*
  • Pelvic Floor
  • Solifenacin Succinate / therapeutic use*
  • Urinary Incontinence, Stress / therapy*
  • Urinary Incontinence, Urge / therapy*
  • Urological Agents / therapeutic use*

Substances

  • Muscarinic Antagonists
  • Urological Agents
  • Solifenacin Succinate